Rani Therapeutics Holdings (RANI) FCF Margin (2020 - 2026)

Rani Therapeutics Holdings has reported FCF Margin for 5 years, with the latest figure at 530.15% in Q2 2026.

• On a quarterly basis, FCF Margin changed N/A year-over-year to 530.15% in Q2 2026; TTM through Jun 2026 was 417.04%, a 218746.0% increase from a year earlier, with the FY2025 full-year figure at 1151.38%, up 232761.0% from the prior year.
• FCF Margin was 530.15% for Q2 2026 at Rani Therapeutics Holdings, down from 381.44% in the prior quarter.
• The five-year high for FCF Margin was 20.12% in Q4 2025, with the low at 4767.44% in Q1 2025.
• Average FCF Margin over 3 years is 1300.77%, with a median of 530.15% recorded in 2026.
• The sharpest annual moves came in 2025 and 2026: FCF Margin surged 86506 bps in 2025, then jumped 438600 bps in 2026.
• Over 3 years, FCF Margin stood at 844.94% in 2024, then soared by 102 bps to 20.12% in 2025, then slumped by 2735 bps to 530.15% in 2026.
• The last three FCF Margin figures came in at 530.15% (Q2 2026), 381.44% (Q1 2026), and 20.12% (Q4 2025), per Business Quant data.